EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Respiratory Syncytial Virus Infection—The Key to Prevent Infantile Disease

Vlad Dima, Adrian Ioan Toma, Roxana Elena Bohîlţea

Romanian Journal of Preventive Medicine · 2022

DOI: 10.3390/rjpm1010032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Romanian Journal of Preventive Medicine, 2022. Verfasst von Vlad Dima und 2 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) causes a spectrum of respiratory diseases in infants and young children that can lead to hospitalizations and many outpatient visits, resulting in a huge public health and economic burden. Most hospitalizations occur in otherwise healthy infants, highlighting the need to protect all infants against RSV. Moreover, there is evidence of an association between RSV respiratory disease in early life and recurrent asthma-like wheezing symptoms. Therefore, RSV is considered a global health priority. However, the only prevention strategy currently available is a monoclonal antibody (mAb) indicated in former preterm infants or those with severe comorbidities, thus leaving the majority of the infant population unprotected against this virus. Therefore, the development of RSV prevention strategies for all infants entering their first RSV season represents a large unmet medical need. Current prevention strategies include maternal immunization, infant immunization with vaccines, and infant immunization with licensed monoclonal antibodies.The use of mAb is limited to a small population of infants and does not provide a solution for the protection of all children, while vaccine development in infants has faced various challenges, including the immaturity of the infant immune system, highlighting that future pediatric vaccines will be the most probably used in older infants (>6 months) and children. Maternal immunization and infant immunization with long-acting monoclonal antibodies are two feasible strategies to protect all children against RSV. Based on current data, immunization of infants with long-acting monoclonal antibodies may represent the most effective approach to protect all children entering their first RSV season.

Zitieren

APA

Dima, V., Toma, A. I., & Bohîlţea, R. E. (2022). Respiratory Syncytial Virus Infection—The Key to Prevent Infantile Disease. Romanian Journal of Preventive Medicine. https://doi.org/10.3390/rjpm1010032

Vancouver

Dima V, Toma AI, Bohîlţea RE. Respiratory Syncytial Virus Infection—The Key to Prevent Infantile Disease. Romanian Journal of Preventive Medicine. 2022. doi:10.3390/rjpm1010032

BibTeX
@article{Dima2022,
  author = {Dima, Vlad and Toma, Adrian Ioan and Bohîlţea, Roxana Elena},
  title = {Respiratory Syncytial Virus Infection—The Key to Prevent Infantile Disease},
  journal = {Romanian Journal of Preventive Medicine},
  year = {2022},
  doi = {10.3390/rjpm1010032}
}
Kostenlos starten →